M. Martín-Salvago (Jaén, Spain)
Hospital Universitario Materno-InfantilAuthor Of 1 Presentation
- B. Vieites (Seville, Spain)
- M. López-García (Seville, Spain)
- M. Martín-Salvago (Jaén, Spain)
- C. Ramírez-Tortosa (Jaén, Spain)
- R. Rezola (Donostia, Spain)
- M. Sancho de Salas (Salamanca, Spain)
- L. López Vilaró (Barcelona, Spain)
- F. Vilardell Villellas (Lleida, Spain)
- O. Burgués (Valencia, Spain)
- B. Fernández-Rodríguez (Santiago de Compostela, Spain)
- L. Alfaro Galán (Seville, Spain)
- V. Peg (Barcelona, Spain)
65P - Patient’s follow-up of NEOVATTL study
Abstract
Background
Sentinel lymph node biopsy has gained attention due to its potential for less invasive management of the axilla and the increasing number of early-stage breast cancer patients treated with neoadjuvant systemic therapy prior to surgery. One-Step Nucleic Acid Amplification (OSNA) assay is an accurate and reliable option for intraoperative molecular analysis of SLN status. NEOVATTL study demonstrates its predictive and prognostic value for non-SLN involvement and disease recurrence in breast cancer patients who had received NST. Therefore, the aim of the study was to show the follow-up of those patients that were recruited in NEOVATTL study and to corroborate the favorable prognosis of the patients with low axillary tumour load.
Methods
This is a multicentric and retrospective study in which the patients underwent intraoperative SLN biopsy after NST. The data was obtained from a Spanish Sentinel Lymph Node database. TTL was defined as the total sum of CK19 mRNA copies in all positive SLNs.
Results
A total of 314 patients were included; 75.0% were cN0 prior to NST. 91.7% received chemotherapy with or without biologic therapy, and 81 patients had a pathologic complete response. TTL was predictive of non-SLN involvement at a cut-off of 15,000 copies/μL had a negative predictive value of 90.5%. TTL was prognostic of disease recurrence and DFS at a cut-off of 25,000 copies/μL.
Conclusions
TTL >15,000 mRNA copies/μL was predictive of non-SLN involvement and TTL >25,000 mRNA copies/μL was associated with a higher risk of disease recurrence in breast cancer patients who had received NST. Follow up between five to ten years have demonstrated a favourable prognosis of patients with low TTL (<15,000mRNA).
Legal entity responsible for the study
Sociedad Española de Senología y Patología Mamaria (SESPM).
Funding
Sysmex España S.L.
Disclosure
All authors have declared no conflicts of interest.